Annual Accounts Payable
$20.89 M
+$6.54 M+45.53%
31 December 2023
Summary:
BioCryst Pharmaceuticals annual accounts payable is currently $20.89 million, with the most recent change of +$6.54 million (+45.53%) on 31 December 2023. During the last 3 years, it has risen by +$2.18 million (+11.65%). BCRX annual accounts payable is now -24.87% below its all-time high of $27.81 million, reached on 31 December 2021.BCRX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$13.48 M
+$5.70 M+73.16%
30 September 2024
Summary:
BioCryst Pharmaceuticals quarterly accounts payable is currently $13.48 million, with the most recent change of +$5.70 million (+73.16%) on 30 September 2024. Over the past year, it has increased by +$2.92 million (+27.59%). BCRX quarterly accounts payable is now -51.52% below its all-time high of $27.81 million, reached on 31 December 2021.BCRX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +45.5% | +27.6% |
| 3 y3 years | +11.7% | -31.5% |
| 5 y5 years | +168.9% | +33.7% |
BCRX Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -24.9% | +45.5% | -51.5% | +115.6% |
| 5 y | 5 years | -24.9% | +168.9% | -51.5% | +115.6% |
| alltime | all time | -24.9% | >+9999.0% | -51.5% | >+9999.0% |
BioCryst Pharmaceuticals Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $13.48 M(+73.2%) |
| June 2024 | - | $7.79 M(-34.6%) |
| Mar 2024 | - | $11.91 M(-43.0%) |
| Dec 2023 | $20.89 M(+45.5%) | $20.89 M(+97.7%) |
| Sept 2023 | - | $10.57 M(-23.9%) |
| June 2023 | - | $13.89 M(+122.1%) |
| Mar 2023 | - | $6.25 M(-56.4%) |
| Dec 2022 | $14.36 M(-48.4%) | $14.36 M(+66.5%) |
| Sept 2022 | - | $8.62 M(-28.3%) |
| June 2022 | - | $12.02 M(-13.4%) |
| Mar 2022 | - | $13.88 M(-50.1%) |
| Dec 2021 | $27.81 M(+48.6%) | $27.81 M(+41.2%) |
| Sept 2021 | - | $19.69 M(+95.2%) |
| June 2021 | - | $10.09 M(-25.4%) |
| Mar 2021 | - | $13.53 M(-27.7%) |
| Dec 2020 | $18.71 M(+33.8%) | $18.71 M(+61.1%) |
| Sept 2020 | - | $11.62 M(+24.2%) |
| June 2020 | - | $9.35 M(-7.0%) |
| Mar 2020 | - | $10.06 M(-28.1%) |
| Dec 2019 | $13.99 M(+80.0%) | $13.99 M(+38.7%) |
| Sept 2019 | - | $10.08 M(+21.5%) |
| June 2019 | - | $8.30 M(+19.7%) |
| Mar 2019 | - | $6.93 M(-10.7%) |
| Dec 2018 | $7.77 M(+22.6%) | $7.77 M(-1.8%) |
| Sept 2018 | - | $7.91 M(+91.9%) |
| June 2018 | - | $4.12 M(+14.9%) |
| Mar 2018 | - | $3.59 M(-43.4%) |
| Dec 2017 | $6.34 M(+48.4%) | $6.34 M(+37.7%) |
| Sept 2017 | - | $4.60 M(+149.6%) |
| June 2017 | - | $1.84 M(-66.1%) |
| Mar 2017 | - | $5.43 M(+27.3%) |
| Dec 2016 | $4.27 M(-54.1%) | $4.27 M(+54.7%) |
| Sept 2016 | - | $2.76 M(-45.4%) |
| June 2016 | - | $5.05 M(-34.3%) |
| Mar 2016 | - | $7.69 M(-17.4%) |
| Dec 2015 | $9.31 M(+226.7%) | $9.31 M(+146.1%) |
| Sept 2015 | - | $3.78 M(-1.0%) |
| June 2015 | - | $3.82 M(-28.0%) |
| Mar 2015 | - | $5.31 M(+86.3%) |
| Dec 2014 | $2.85 M(-31.7%) | $2.85 M(+25.7%) |
| Sept 2014 | - | $2.27 M(-4.0%) |
| June 2014 | - | $2.36 M(+74.6%) |
| Mar 2014 | - | $1.35 M(-67.6%) |
| Dec 2013 | $4.17 M(+5.0%) | $4.17 M(+236.3%) |
| Sept 2013 | - | $1.24 M(+25.5%) |
| June 2013 | - | $989.00 K(-7.8%) |
| Mar 2013 | - | $1.07 M(-73.0%) |
| Dec 2012 | $3.97 M(+59.2%) | $3.97 M(+73.3%) |
| Sept 2012 | - | $2.29 M(-31.1%) |
| June 2012 | - | $3.33 M(+61.4%) |
| Mar 2012 | - | $2.06 M(-17.4%) |
| Dec 2011 | $2.50 M(-69.6%) | $2.50 M(-30.3%) |
| Sept 2011 | - | $3.58 M(-28.5%) |
| June 2011 | - | $5.01 M(-19.9%) |
| Mar 2011 | - | $6.25 M(-23.7%) |
| Dec 2010 | $8.20 M(-54.6%) | $8.20 M(+151.5%) |
| Sept 2010 | - | $3.26 M(+126.8%) |
| June 2010 | - | $1.44 M(-77.4%) |
| Mar 2010 | - | $6.35 M(-64.8%) |
| Dec 2009 | $18.07 M | $18.07 M(+464.7%) |
| Sept 2009 | - | $3.20 M(+14.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2009 | - | $2.79 M(-33.3%) |
| Mar 2009 | - | $4.18 M(-20.5%) |
| Dec 2008 | $5.27 M(-73.4%) | $5.27 M(+62.6%) |
| Sept 2008 | - | $3.24 M(-65.2%) |
| June 2008 | - | $9.32 M(-36.9%) |
| Mar 2008 | - | $14.76 M(-25.3%) |
| Dec 2007 | $19.77 M(+235.8%) | $19.77 M(+20.7%) |
| Sept 2007 | - | $16.38 M(+54.9%) |
| June 2007 | - | $10.58 M(+28.9%) |
| Mar 2007 | - | $8.21 M(+39.4%) |
| Dec 2006 | $5.89 M(-33.2%) | $5.89 M(-26.2%) |
| Sept 2006 | - | $7.97 M(+53.2%) |
| June 2006 | - | $5.21 M(-24.2%) |
| Mar 2006 | - | $6.87 M(-22.1%) |
| Dec 2005 | $8.81 M(+347.3%) | $8.81 M(+295.0%) |
| Sept 2005 | - | $2.23 M(+84.7%) |
| June 2005 | - | $1.21 M(-27.8%) |
| Mar 2005 | - | $1.67 M(-15.1%) |
| Dec 2004 | $1.97 M(+207.7%) | $1.97 M(-2.6%) |
| Sept 2004 | - | $2.02 M(+138.4%) |
| June 2004 | - | $849.00 K(-19.4%) |
| Mar 2004 | - | $1.05 M(+64.6%) |
| Dec 2003 | $640.30 K(+150.1%) | $640.30 K(+39.5%) |
| Sept 2003 | - | $459.00 K(-25.6%) |
| June 2003 | - | $617.00 K(+127.7%) |
| Mar 2003 | - | $271.00 K(+5.9%) |
| Dec 2002 | $256.00 K(-58.5%) | $256.00 K(-44.3%) |
| Sept 2002 | - | $460.00 K(-40.6%) |
| June 2002 | - | $775.00 K(+121.4%) |
| Mar 2002 | - | $350.00 K(-43.3%) |
| Dec 2001 | $617.60 K(-23.2%) | $617.60 K(+68.3%) |
| Sept 2001 | - | $367.00 K(+25.7%) |
| June 2001 | - | $292.00 K(+21.7%) |
| Mar 2001 | - | $240.00 K(-70.2%) |
| Dec 2000 | $804.10 K(+168.0%) | $804.10 K(+216.6%) |
| Sept 2000 | - | $254.00 K(-72.2%) |
| June 2000 | - | $915.00 K(+125.8%) |
| Mar 2000 | - | $405.20 K(+35.1%) |
| Dec 1999 | $300.00 K(+50.0%) | $300.00 K(+200.0%) |
| Sept 1999 | - | $100.00 K(-66.7%) |
| June 1999 | - | $300.00 K(+50.0%) |
| Mar 1999 | - | $200.00 K(0.0%) |
| Dec 1998 | $200.00 K(0.0%) | $200.00 K(-60.0%) |
| Sept 1998 | - | $500.00 K(+66.7%) |
| June 1998 | - | $300.00 K(-57.1%) |
| Mar 1998 | - | $700.00 K(+250.0%) |
| Dec 1997 | $200.00 K(-66.7%) | $200.00 K(-66.7%) |
| Sept 1997 | - | $600.00 K(-14.3%) |
| June 1997 | - | $700.00 K(0.0%) |
| Mar 1997 | - | $700.00 K(+16.7%) |
| Dec 1996 | $600.00 K(+50.0%) | $600.00 K(0.0%) |
| Sept 1996 | - | $600.00 K(-25.0%) |
| June 1996 | - | $800.00 K(+100.0%) |
| Mar 1996 | - | $400.00 K(0.0%) |
| Dec 1995 | $400.00 K(+33.3%) | $400.00 K(+33.3%) |
| Sept 1995 | - | $300.00 K(-25.0%) |
| June 1995 | - | $400.00 K(+100.0%) |
| Mar 1995 | - | $200.00 K(-33.3%) |
| Dec 1994 | $300.00 K | $300.00 K(-25.0%) |
| Sept 1994 | - | $400.00 K(-42.9%) |
| June 1994 | - | $700.00 K(0.0%) |
| Mar 1994 | - | $700.00 K |
FAQ
- What is BioCryst Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual accounts payable year-on-year change?
- What is BioCryst Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly accounts payable year-on-year change?
What is BioCryst Pharmaceuticals annual accounts payable?
The current annual accounts payable of BCRX is $20.89 M
What is the all time high annual accounts payable for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual accounts payable is $27.81 M
What is BioCryst Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, BCRX annual accounts payable has changed by +$6.54 M (+45.53%)
What is BioCryst Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of BCRX is $13.48 M
What is the all time high quarterly accounts payable for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly accounts payable is $27.81 M
What is BioCryst Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, BCRX quarterly accounts payable has changed by +$2.92 M (+27.59%)